

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
12 June 2025 (12.06.2025)



(10) International Publication Number
WO 2025/122747 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 45/06 (2006.01)
A61K 31/05 (2006.01) A61P 11/06 (2006.01)
A61K 31/56 (2006.01)

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/058667

(22) International Filing Date:

05 December 2024 (05.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/606,952 06 December 2023 (06.12.2023) US
63/637,741 23 April 2024 (23.04.2024) US

(71) Applicant: PRINCIPIA BIOPHARMA INC. [US/US];

55 Corporate Drive, Bridgewater, New Jersey 08807 (US).

(72) Inventors: GEREIGE, Jessica; c/o Sanofi, Patent Department,

450 Water Street, Cambridge, Massachusetts 02141 (US).

GOSSAGE, David; c/o Sanofi, Patent Department,

450 Water Street, Cambridge, Massachusetts 02141 (US).

MANNENT, Leda; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR).

MARTINCOVA, Renata; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR).

MIKOL, Vincent; c/o Sanofi, Patent Department, 46 avenue de la Grande Armée, 75017 Paris (FR).

SURATT, Benjamin; c/o Sanofi, Patent Department, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: WINKLER, Lauren N. et al.; McNeill PLLC, 245

First Street, 18th Floor, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,

KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,

RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,

ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

(54) Title: TREATMENT OF MODERATE-TO-SEVERE ASTHMA BY ADMINISTERING RILZABRUTINIB

(57) Abstract: Methods for treating patients with moderate-to-severe asthma comprising administering a therapeutically effective amount of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof are disclosed.



WO 2025/122747 A1